Filtered By:
Condition: Atrial Fibrillation
Drug: Warfarin

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 2924 results found since Jan 2013.

Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation
Background: Oral anticoagulants (OACs) reduce the incidence of embolic events associated with non-valvular atrial fibrillation (NVAF); however, ischemic stroke can still occur in such patients. Although there are various causes of ischemic stroke in patients with NVAF, their medication status at onset has scarcely been studied. This retrospective study aimed to determine the underlying causes of ischemic stroke in patients with NVAF in relation to pre-stroke anticoagulation. Methods: Among Japanese patients with acute ischemic stroke enrolled in the Fukuoka Stroke Registry from June 2007 to May 2013, 1,302 patients with NV...
Source: Cerebrovascular Diseases - April 26, 2016 Category: Neurology Source Type: research

Atrial fibrillation and risk of stroke: a nationwide cohort study
Conclusions Stroke/TE/TIA risk was particularly increased when prior stroke/TE/TIA was present. Atrial fibrillation is associated with an increase in risk of stroke/TE/TIA in the absence of other risk factors but only a moderate increase in risk when other risk factors are present.
Source: Europace - November 1, 2016 Category: Cardiology Authors: Christiansen, C. B., Gerds, T. A., Olesen, J. B., Kristensen, S. L., Lamberts, M., Lip, G. Y. H., Gislason, G. H., Kober, L., Torp-Pedersen, C. Tags: Atrial fibrillation Source Type: research

TCT 2017: Boston Scientific touts lowered hemorrhagic stroke rate, cost for patients in Watchman studies
Boston Scientific (NYSE:BSX) today released combined 5-year outcomes data from both the Prevail and Protect-AF study of its Watchman left atrial appendage closure device, touting it as a safe and effective an alternative to long-term warfarin therapy for patients with non-valvular atrial fibrillation. Five-year data from the Prevail study was published online today in the Journal of the American College of Cardiology. In both trials, the Marlborough, Mass.-based company compared the Watchman device to warfarin treatment for stroke prevention in patients with non-valvular AF with follow-ups out to five years. A combined an...
Source: Mass Device - November 2, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Boston Scientific Source Type: news

Factors associated with ischemic stroke on therapeutic anticoagulation in patients with nonvalvular atrial fibrillation.
CONCLUSION: NVAF patients with high CHADS₂/CHA₂DS₂-VASc scores and a previous ischemic stroke or smoking history are at high risk of stroke despite optimal warfarin treatment. Some other measures to reduce the risk of stroke would be necessary in those specific groups of patients. PMID: 25683989 [PubMed - in process]
Source: Yonsei Medical Journal - February 19, 2015 Category: Universities & Medical Training Authors: Kim YD, Lee KY, Nam HS, Han SW, Lee JY, Cho HJ, Kim GS, Kim SH, Cha MJ, Ahn SH, Oh SH, Lee KO, Jung YH, Choi HY, Han SD, Lee HS, Nam CM, Kim EH, Lee KJ, Song D, Park HN, Heo JH Tags: Yonsei Med J Source Type: research

Stroke Risk Reduction Outweighed Bleeding Risk Increase from Vitamin K Antagonists Treatment among Nonvalvular Atrial Fibrillation Patients with High Stroke risk and Low Bleeding Risk.
CONCLUSION: In NVAF patients at high risk for stroke and low risk for bleeding, our data confirm the effectiveness of anticoagulation for stroke prevention. The decrease in stroke risk of anticoagulation may outweigh the risk of major bleeding events, particularly among elderly patients. Potential risks of warfarin during initiation warrant attention, especially among patients who stop and start therapy repeatedly. PMID: 28008771 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - December 25, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research

The CHA2DS2-VASc score and the risk of ischemic stroke in community-dwelling individuals with and without atrial fibrillation: The Atherosclerosis Risk In Communities (ARIC) study
Conclusion The risk of ischemic stroke is low across CHA2DS2-VASc score categories in community-dwelling individuals without AF. Individuals with AF are at high risk for ischemic stroke even with low CHA2DS2-VASc score, suggesting the need for stroke prevention in individuals with AF and one CHA2DS2-VASc stroke risk factor.
Source: Journal of the Saudi Heart Association - July 8, 2017 Category: Cardiology Source Type: research

Warfarin Use, Stroke, and Bleeding Risk among Pre-Existing Atrial Fibrillation US Veterans Transitioning to Dialysis
In this study, we validated risk scores for stroke and bleeding in this population and assessed risk of stroke and bleeding among warfarin users compared to nonusers.Methods: We utilized a cohort of 28,620 pre-dialysis US veterans transitioning to hemodialysis between October 2007 and March 2015. Incident rates for the risks of stroke and bleeding were ascertained based upon CHA2DS2-VASc or HAS-BLED scores, respectively. A propensity score-based competing risk analysis was used to assess risk of stroke and bleeding.Findings: The mean age of our cohort was 77 ± 9 years, and the median CHA2DS2-VASc and HAS-BLED scores were ...
Source: Nephron - February 4, 2022 Category: Urology & Nephrology Source Type: research

Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry Original Articles
Conclusions— In community-based outpatients with AF, use of OAC was high and driven by not only predominantly stroke but also bleeding risk. Stroke risk significantly affects OAC use among those with low bleeding risk, whereas those with high bleeding risk demonstrate consistently lower use of OAC regardless of stroke risk.
Source: Circulation: Cardiovascular Quality and Outcomes - July 16, 2013 Category: Cardiology Authors: Cullen, M. W., Kim, S., Piccini, J. P., Ansell, J. E., Fonarow, G. C., Hylek, E. M., Singer, D. E., Mahaffey, K. W., Kowey, P. R., Thomas, L., Go, A. S., Lopes, R. D., Chang, P., Peterson, E. D., Gersh, B. J., on behalf of the ORBIT-AF Investigators Tags: Coumarins, Arrhythmias, clinical electrophysiology, drugs, Embolic stroke, Risk Factors for Stroke, Anticoagulants Original Articles Source Type: research

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Abstract Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported. In the absence of head to head trials directly comparing these NOACs against each other, we compared the efficacy and safety of edoxaban to other agents by an indirect comparison analysis. We performed an indirect comparison analysis of edoxaban (2 dose strategies) against apixaban (1 dose), dabigatran etexilate (2 doses) and rivaroxaban (1 dose), for their relative efficacy and safety against ea...
Source: Thrombosis and Haemostasis - February 28, 2014 Category: Hematology Authors: Skjøth F, Larsen TB, Rasmussen LH, Lip GY Tags: Thromb Haemost Source Type: research

Thoracoscopic Pulmonary Vein Isolation and Atrial Appendage Ligation (TPVIAL) versus Medical Management in Atrial Fibrillation Patients with Prior Stroke (P1.126)
CONCLUSIONS: TPVIAL may become an important therapeutic tool for reducing recurrent stroke in AF patients.Disclosure: Dr. Waters has nothing to disclose. Dr. Hedna has nothing to disclose. Dr. Khanna has nothing to disclose. Dr. Miles has nothing to disclose. Dr. Price has nothing to disclose. Dr. Schmalfuss has nothing to disclose. Dr. Robertson has nothing to disclose. Dr. Karimi has nothing to disclose. Dr. Beaver has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Waters, M., Hedna, V., Khanna, A., Miles, W., Price, C., Schmalfuss, I., Robertson, D., Karimi, A., Beaver, T. Tags: Cerebrovascular Disease and Interventional Neurology: Atrial Fibrillation and Miscellaneous Source Type: research

Abstract 263: The Risk of Stroke or Systemic Embolism for Antithrombotic Treatment Episodes among Non-Valvular Atrial Fibrillation (NVAF) Patients Session Title: Poster Session II
Conclusion: Warfarin TTR ≥55% was associated with the greatest reduction in stroke/SE among the antithrombotic treatment groups examine here. Future studies should examine modifiable factors to improve outcomes for patients with warfarin TTR <55% or those who are off antithrombotic therapy.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: An, J., Niu, F., Lang, D. T., Le, P. T., Jazdzewski, K. P., Rashid, N., Mendes, R., Dills, D., Meissner, B., Bruno, A. Tags: Session Title: Poster Session II Source Type: research

Clinical Features of Ischemic Stroke during Treatment with Dabigatran: An Association between Decreased Severity and a Favorable Prognosis.
Conclusion Dabigatran may therefore decrease the severity of ischemic stroke, even if ischemic stroke occurs. PMID: 26424298 [PubMed - in process]
Source: Internal Medicine - October 2, 2015 Category: Internal Medicine Tags: Intern Med Source Type: research

Warfarin Use and Risk of Stroke in Patients With Atrial Fibrillation Undergoing Hemodialysis: A Meta-Analysis
Abstract: In spite of the substantial burden of atrial fibrillation and associated elevated ischemic stroke risk in patients undergoing hemodialysis, the role of warfarin in these high-risk patients remains uncertain. Our objective was to clarify the association between warfarin use and risk of stroke for patients with atrial fibrillation undergoing dialysis. PubMed and Embase from January 1966 to January 2015 were searched to identify relevant studies. Inclusion criteria were cohort studies, patients with atrial fibrillation undergoing hemodialysis, and reported quantitative estimates of the multivariate adjusted relativ...
Source: Medicine - February 1, 2016 Category: Internal Medicine Tags: Research Article: Meta-Analysis of Observ Studies in Epidemiology Source Type: research

Acute Management of Stroke Patients Taking Non-vitamin K Antagonist Oral Anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and Rationale
Conclusion The ARAMIS Registry will document the current state of management of NOAC treated patients with acute ischemic stroke as well as contemporary care and outcome of anticoagulation-related intracerebral hemorrhage. These data will be used to better understand optimal strategies to care for these complex but increasingly common emergent real world clinical challenges.
Source: American Heart Journal - August 26, 2016 Category: Cardiology Source Type: research

Acute management of stroke patients taking non –vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale
Conclusion The ARAMIS Registry will document the current state of management of NOAC treated patients with acute ischemic stroke as well as contemporary care and outcome of anticoagulation-related intracerebral hemorrhage. These data will be used to better understand optimal strategies to care for these complex but increasingly common emergent real world clinical challenges.
Source: American Heart Journal - September 23, 2016 Category: Cardiology Source Type: research